Press release
Mucopolysaccharidosis Market Growth to Surge During Forecast Period (2024-2034), Says DelveInsight
The latest healthcare forecast report provides an in-depth analysis of Mucopolysaccharidosis, offering comprehensive insights into the Mucopolysaccharidosis revenue trends, prevalence, and treatment landscape. The report delves into key Mucopolysaccharidosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Mucopolysaccharidosis therapies. Additionally, we cover the landscape of Mucopolysaccharidosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Mucopolysaccharidosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Mucopolysaccharidosis space.
To Know in detail about the Mucopolysaccharidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Mucopolysaccharidosis Market Forecast
https://www.delveinsight.com/sample-request/mucopolysaccharidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Mucopolysaccharidosis Market Report:
• The Mucopolysaccharidosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2025, The FDA has accepted REGENXBIO's Biologics License Application (BLA) for clemidsogene lanparvovec (RGX-121), an investigational gene therapy using an adeno-associated virus vector for the treatment of mucopolysaccharidosis type II (MPS II or Hunter syndrome). The application has been granted priority review, with a Prescription Drug User Fee Act (PDUFA) target action date set for November 9, 2025. REGENXBIO President and CEO Curran M. Simpson stated that the acceptance represents a major milestone toward offering patients a potential one-time treatment that could impact both the neurodevelopmental and systemic symptoms of Hunter syndrome.
• Key Mucopolysaccharidosis Companies: JCR Pharmaceuticals, Denali Therapeutics Inc., Genzyme, Alexion Pharmaceuticals, Lynda E Polgreen, BioMarin Pharmaceutical, Inventiva Pharma, ArmaGen, Inc, and others
• Key Mucopolysaccharidosis Therapies: JR-171, tividenofusp alfa, Laronidase, SBC-103, anakinra, N-acetylgalactosamine 4-sulfatase, Odiparcil, AGT-181, and others
• The Mucopolysaccharidosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Mucopolysaccharidosis pipeline products will significantly revolutionize the Mucopolysaccharidosis market dynamics.
• Mucopolysaccharidosis is an ultra-rare lysosomal storage disorder with a low prevalence across the 7MM.
• The combined prevalence of all MPS types in the 7MM is estimated to be approximately 1 in 25,000 to 1 in 50,000 live births.
• The United States reports the highest diagnosed population due to better screening and awareness programs.
• Germany and France lead in diagnosed MPS cases within the EU4, while the UK also shows a considerable number of diagnosed cases.
• Among all subtypes, MPS I (Hurler syndrome) and MPS II (Hunter syndrome) are the most frequently diagnosed in the 7MM.
• Pediatric Population Impact: MPS primarily affects children, with symptoms typically appearing in early childhood.
• Gender Disparity in MPS II: MPS II (Hunter syndrome) is X-linked, primarily affecting male patients.
Mucopolysaccharidosis Overview
Mucopolysaccharidosis (MPS) is a group of rare inherited metabolic disorders caused by the absence or malfunction of specific enzymes needed to break down glycosaminoglycans (formerly called mucopolysaccharides). These complex carbohydrates accumulate in cells, blood, and connective tissues, leading to progressive damage to the heart, bones, joints, respiratory system, and central nervous system. Symptoms vary depending on the type of MPS but may include abnormal facial features, developmental delays, enlarged organs, joint stiffness, and heart problems. MPS is typically diagnosed in childhood and currently has no cure, though enzyme replacement therapy and supportive treatments can help manage symptoms and improve quality of life.
Get a Free sample for the Mucopolysaccharidosis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/mucopolysaccharidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Mucopolysaccharidosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Mucopolysaccharidosis Epidemiology Segmentation:
The Mucopolysaccharidosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Mucopolysaccharidosis
• Prevalent Cases of Mucopolysaccharidosis by severity
• Gender-specific Prevalence of Mucopolysaccharidosis
• Diagnosed Cases of Episodic and Chronic Mucopolysaccharidosis
Download the report to understand which factors are driving Mucopolysaccharidosis epidemiology trends @ Mucopolysaccharidosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/mucopolysaccharidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Mucopolysaccharidosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mucopolysaccharidosis market or expected to get launched during the study period. The analysis covers Mucopolysaccharidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Mucopolysaccharidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Mucopolysaccharidosis Therapies and Key Companies
• JR-171: JCR Pharmaceuticals
• tividenofusp alfa: Denali Therapeutics Inc.
• Laronidase: Genzyme
• SBC-103: Alexion Pharmaceuticals
• anakinra: Lynda E Polgreen
• N-acetylgalactosamine 4-sulfatase: BioMarin Pharmaceutical
• Odiparcil: Inventiva Pharma
• AGT-181: ArmaGen, Inc
Discover more about therapies set to grab major Mucopolysaccharidosis market share @ Mucopolysaccharidosis Treatment Landscape
https://www.delveinsight.com/sample-request/mucopolysaccharidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Mucopolysaccharidosis Market Drivers
• Growing Awareness and Early Diagnosis
• Advancements in Genetic and Enzyme Replacement Therapies
• Rising Investments in Rare Disease Research
• Expanding Newborn Screening Programs
• Regulatory Incentives for Orphan Drugs
Mucopolysaccharidosis Market Barriers
• High Treatment Costs
• Limited Treatment Options
• Delayed Diagnosis
• Small Patient Population
• Access and Reimbursement Challenges
Scope of the Mucopolysaccharidosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Mucopolysaccharidosis Companies: JCR Pharmaceuticals, Denali Therapeutics Inc., Genzyme, Alexion Pharmaceuticals, Lynda E Polgreen, BioMarin Pharmaceutical, Inventiva Pharma, ArmaGen, Inc, and others
• Key Mucopolysaccharidosis Therapies: JR-171, tividenofusp alfa, Laronidase, SBC-103, anakinra, N-acetylgalactosamine 4-sulfatase, Odiparcil, AGT-181, and others
• Mucopolysaccharidosis Therapeutic Assessment: Mucopolysaccharidosis current marketed and Mucopolysaccharidosis emerging therapies
• Mucopolysaccharidosis Market Dynamics: Mucopolysaccharidosis market drivers and Mucopolysaccharidosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Mucopolysaccharidosis Unmet Needs, KOL's views, Analyst's views, Mucopolysaccharidosis Market Access and Reimbursement
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mucopolysaccharidosis Market Growth to Surge During Forecast Period (2024-2034), Says DelveInsight here
News-ID: 4183492 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Mucopolysaccharidosis
Mucopolysaccharidosis I (MPS I) Market Emerging Trends and Growth Prospects 2034
Introduction
Mucopolysaccharidosis I (MPS I) is a rare lysosomal storage disorder caused by the deficiency of the enzyme α-L-iduronidase, leading to progressive multisystemic complications including skeletal deformities, organ dysfunction, and neurological decline in severe cases. The disease is categorized into Hurler, Hurler-Scheie, and Scheie syndromes, each varying in severity.
Over the past two decades, the availability of enzyme replacement therapy (ERT) has significantly improved patient outcomes, while hematopoietic stem cell transplantation (HSCT)…
Mucopolysaccharidosis Market Set to Hit USD 3.65 Billion by 2034
Mucopolysaccharidosis (MPS) is a group of rare, inherited metabolic disorders caused by the absence or malfunction of enzymes needed to break down glycosaminoglycans (GAGs). These conditions, including Hurler syndrome (MPS I), Hunter syndrome (MPS II), Sanfilippo syndrome (MPS III), and others, are progressive and can affect physical and cognitive development.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71067
Over the past decade, orphan drug development, advancements in enzyme replacement therapy…
Mucopolysaccharidosis Treatment Market: A Robust Growth Driven by Advancements a …
Understanding the Steady Rise in Global Mucopolysaccharidosis Treatment Market: Focus on Market Size and Growth Rate
- The mucopolysaccharidosis treatment market demonstrated strong growth in recent times, increasing from $2.4 billion in 2024 to an expected $2.59 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%.
- The growth in this historic period is primarily backed by initiatives such as enzyme replacement therapy (ERT), improved diagnostic tools, focused advocacy…
Mucopolysaccharidosis Treatment Market Analysis, Keyplayers, Share And Forecast …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Mucopolysaccharidosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $3.19 billion In 2028 At…
Mucopolysaccharidosis Treatment Market Size, Trends, Leading Players, Share And …
The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033
The Business Research Company offers in-depth market insights through Mucopolysaccharidosis Treatment Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The mucopolysaccharidosis treatment market size has grown strongly in recent years. It…
Gene Therapy for Mucopolysaccharidosis Market to Witness Growth Acceleration by …
Gene Therapy for Mucopolysaccharidosis Market is expected to witness moderate growth registering 9.4% CAGR during the forecast period (2023-2029).
Important changes in the business allow key players to attain larger profits. This Gene Therapy for Mucopolysaccharidosis Market study report is the best way to make changes with the help of entire market condition and metrics provided here. These metrics also allow getting ahead in the industry. Furthermore, this market report makes…
